Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 165974, 16 pages
http://dx.doi.org/10.1155/2013/165974
Review Article

Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated View

1Department of Internal Medicine, Yale University School of Medicine, The Anlyan Center, S525, P.O. Box 208031, 300 Cedar Street, New Haven, CT 06520-8031, USA
2Institute of Biochemistry and Molecular Cell Biology, University Hospital of RWTH Aachen University, Pauwelsstraße 30, 52074 Aachen, Germany

Received 5 October 2012; Accepted 22 May 2013

Academic Editor: Celeste C. Finnerty

Copyright © 2013 Wibke Schulte et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Bone, R. A. Balk, F. B. Cerra et al., “Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine,” Chest, vol. 101, no. 6, pp. 1644–1655, 1992. View at Google Scholar · View at Scopus
  2. D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care,” Critical Care Medicine, vol. 29, no. 7, pp. 1303–1310, 2001. View at Google Scholar · View at Scopus
  3. G. S. Martin, D. M. Mannino, S. Eaton, and M. Moss, “The epidemiology of sepsis in the United States from 1979 through 2000,” The New England Journal of Medicine, vol. 348, no. 16, pp. 1546–1554, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Y. Dombrovskiy, A. A. Martin, J. Sunderram, and H. L. Paz, “Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003,” Critical Care Medicine, vol. 35, no. 5, pp. 1244–1250, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Anel and A. Kumar, “Human endotoxemia and human sepsis: limits to the model,” Critical Care, vol. 9, no. 2, pp. 151–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. T. van der Poll and S. M. Opal, “Host-pathogen interactions in sepsis,” The Lancet Infectious Diseases, vol. 8, no. 1, pp. 32–43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. N. Chalupka and D. Talmor, “The economics of sepsis,” Critical Care Clinics, vol. 28, no. 1, pp. 57–76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Burchardi and H. Schneider, “Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy,” PharmacoEconomics, vol. 22, no. 12, pp. 793–813, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Geroulanos and E. T. Douka, “Historical perspective of the word ‘sepsis’,” Intensive Care Medicine, vol. 32, no. 12, p. 2077, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. R. P. Dellinger, M. M. Levy, A. Rhodes et al., “Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012,” Critical Care Medicine, vol. 41, no. 2, pp. 580–637, 2013. View at Google Scholar
  11. M. M. Levy, M. P. Fink, J. C. Marshall et al., “2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference,” Critical Care Medicine, vol. 31, no. 4, pp. 1250–1256, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Alberti, C. Brun-Buisson, S. V. Goodman et al., “Influence of systemic inflammatory response syndrome and sepsis on outcome of critically III infected patients,” American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 1, pp. 77–84, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Alberti, C. Brun-Buisson, S. Chevret et al., “Systemic inflammatory response and progression to severe sepsis in critically ill infected patients,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 5, pp. 461–468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Pittet, S. Rangel-Frausto, N. Li et al., “Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients,” Intensive Care Medicine, vol. 21, no. 4, pp. 302–309, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. R. P. Dellinger, J. M. Carlet, H. Masur et al., “Surviving sepsis campaign guidelines for management of severe sepsis and septic shock,” Critical Care Medicine, vol. 32, no. 3, pp. 858–873, 2004. View at Google Scholar
  16. J. Cohen, “The immunopathogenesis of sepsis,” Nature, vol. 420, no. 6917, pp. 885–891, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. J. D. Hansen, L. N. Vojtech, and K. J. Laing, “Sensing disease and danger: a survey of vertebrate PRRs and their origins,” Developmental and Comparative Immunology, vol. 35, no. 9, pp. 886–897, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Rivers, B. Nguyen, S. Havstad et al., “Early goal-directed therapy in the treatment of severe sepsis and septic shock,” The New England Journal of Medicine, vol. 345, no. 19, pp. 1368–1377, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Denk, M. Perl, and M. Huber-Lang, “Damage- and pathogen-associated molecular patterns and alarmins: keys to sepsis?” European Surgical Research, vol. 48, no. 4, pp. 171–179, 2012. View at Google Scholar
  20. M. Levi and T. van der Poll, “Inflammation and coagulation,” Critical Care Medicine, vol. 38, supplement 2, pp. S26–S34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Atsumi, Y. Cho, L. Leng et al., “The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation,” The Journal of Immunology, vol. 179, no. 8, pp. 5399–5406, 2007. View at Google Scholar · View at Scopus
  22. B. Mlinar and J. Marc, “New insights into adipose tissue dysfunction in insulin resistance,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 12, pp. 1925–1935, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Emonts, F. C. G. J. Sweep, N. Grebenchtchikov et al., “Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis,” Clinical Infectious Diseases, vol. 44, no. 10, pp. 1321–1328, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Capuron and A. H. Miller, “Immune system to brain signaling: neuropsychopharmacological implications,” Pharmacology and Therapeutics, vol. 130, no. 2, pp. 226–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. K. M. Hook and C. S. Abrams, “The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients,” Clinical and Translational Science, vol. 5, no. 1, pp. 85–92, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. R. S. Hotchkiss and D. W. Nicholson, “Apoptosis and caspases regulate death and inflammation in sepsis,” Nature Reviews Immunology, vol. 6, no. 11, pp. 813–822, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Volk, P. Reinke, and W. Döcke, “Clinical aspects: from systemic inflammation to ‘immunoparalysis’,” Chemical Immunology, vol. 74, pp. 162–177, 2000. View at Google Scholar · View at Scopus
  28. R. N. Germain, “Maintaining system homeostasis: the third law of Newtonian immunology,” Nature Immunology, vol. 13, no. 10, pp. 902–906, 2012. View at Google Scholar
  29. R. S. Hotchkiss and S. Opal, “Immunotherapy for sepsis—a new approach against an ancient foe,” The New England Journal of Medicine, vol. 363, no. 1, pp. 87–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. K. J. Ishii, S. Koyama, A. Nakagawa, C. Coban, and S. Akira, “Host innate immune receptors and beyond: making sense of microbial infections,” Cell Host and Microbe, vol. 3, no. 6, pp. 352–363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Akira and K. Takeda, “Toll-like receptor signalling,” Nature Reviews Immunology, vol. 4, no. 7, pp. 499–511, 2004. View at Google Scholar · View at Scopus
  33. S. A. Lakhani and C. W. Bogue, “Toll-like receptor signaling in sepsis,” Current Opinion in Pediatrics, vol. 15, no. 3, pp. 278–282, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. L. A. J. O'Neill, “A critical role for citrate metabolism in LPS signalling,” Biochemical Journal, vol. 438, no. 3, pp. e5–e6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Jawien, “New insights into immunological aspects of atherosclerosis,” Polskie Archiwum Medycyny Wewnetrznej, vol. 118, no. 3, pp. 127–131, 2008. View at Google Scholar
  36. E. Choy, “Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis,” Rheumatology, vol. 51, supplement 5, pp. v3–v11, 2012. View at Google Scholar
  37. N. Parameswaran and S. Patial, “Tumor necrosis factor-a signaling in macrophages,” Critical Reviews in Eukaryotic Gene Expression, vol. 20, no. 2, pp. 87–103, 2010. View at Google Scholar · View at Scopus
  38. J. M. Rubio-Perez and J. M. Morillas-Ruiz, “A review: inflammatory process in Alzheimer's disease, role of cytokines,” The Scientific World Journal, vol. 2012, Article ID 756357, 15 pages, 2012. View at Publisher · View at Google Scholar
  39. C. A. Dinarello, “Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed,” Journal of Endotoxin Research, vol. 10, no. 4, pp. 201–222, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Feldmann, F. M. Brennan, M. Elliott, P. Katsikis, and R. N. Maini, “TNFα as a therapeutic target in rheumatoid arthritis,” Circulatory Shock, vol. 43, no. 4, pp. 179–184, 1994. View at Google Scholar · View at Scopus
  41. B. Modzelewski, “The role of soluble TNF p55 and p75 receptors in the development of septic syndrome,” Polski Merkuriusz Lekarski, vol. 14, no. 79, pp. 69–72, 2003. View at Google Scholar · View at Scopus
  42. M. Schouten, W. J. Wiersinga, M. Levi, and T. van der Poll, “Inflammation, endothelium, and coagulation in sepsis,” Journal of Leukocyte Biology, vol. 83, no. 3, pp. 536–545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. L. Witsell and L. B. Schook, “Tumor necrosis factor alpha is an autocrine growth regulator during macrophage differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4754–4758, 1992. View at Google Scholar
  44. C. A. Dinarello, “Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock,” Chest, vol. 112, supplement 6, pp. 321S–329S, 1997. View at Google Scholar · View at Scopus
  45. C. J. Fisher Jr., J. M. Agosti, S. M. Opal et al., “Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group,” The New England Journal of Medicine, vol. 334, no. 26, pp. 1697–1702, 1996. View at Google Scholar
  46. Y. Fong, K. J. Tracey, L. L. Moldawer et al., “Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia,” Journal of Experimental Medicine, vol. 170, no. 5, pp. 1627–1633, 1989. View at Google Scholar · View at Scopus
  47. L. A. J. O'Neill, “The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress,” Immunological Reviews, vol. 226, no. 1, pp. 10–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Ohlsson, P. Bjork, M. Bergenfeldt, R. Hageman, and R. C. Thompson, “Interleukin-1 receptor antagonist reduces mortality from endotoxin shock,” Nature, vol. 348, no. 6301, pp. 550–552, 1990. View at Publisher · View at Google Scholar · View at Scopus
  49. E. C. Borden and P. Chin, “Interleukin-6: a cytokine with potential diagnostic and therapeutic roles,” Journal of Laboratory and Clinical Medicine, vol. 123, no. 6, pp. 824–829, 1994. View at Google Scholar · View at Scopus
  50. Z. Chai, S. Gatti, C. Toniatti, V. Poli, and T. Bartfai, “Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1β: a study on IL- 6-deficient mice,” Journal of Experimental Medicine, vol. 183, no. 1, pp. 311–316, 1996. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Kopf, H. Baumann, G. Freer et al., “Impaired immune and acute-phase responses in interleukin-6-deficient mice,” Nature, vol. 368, no. 6469, pp. 339–342, 1994. View at Publisher · View at Google Scholar · View at Scopus
  52. M. W. N. Nijsten, C. E. Hack, M. Helle, H. J. Ten Duis, H. J. Klasen, and L. A. Aarden, “Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients,” Surgery, vol. 109, no. 6, pp. 761–767, 1991. View at Google Scholar · View at Scopus
  53. D. A. Papanicolaou, R. L. Wilder, S. C. Manolagas, and G. P. Chrousos, “The pathophysiologic roles of interleukin-6 in human disease,” Annals of Internal Medicine, vol. 128, no. 2, pp. 127–137, 1998. View at Google Scholar · View at Scopus
  54. J. Y. Park and M. H. Pillinger, “Interleukin-6 in the pathogenesis of rheumatoid arthritis,” Bulletin of the NYU hospital for joint diseases, vol. 65, supplement 1, pp. S4–S10, 2007. View at Google Scholar · View at Scopus
  55. A. M. W. Petersen and B. K. Pedersen, “The anti-inflammatory effect of exercise,” Journal of Applied Physiology, vol. 98, no. 4, pp. 1154–1162, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Scheller and S. Rose-John, “Interleukin-6 and its receptor: from bench to bedside,” Medical Microbiology and Immunology, vol. 195, no. 4, pp. 173–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Schindler, J. Mancilla, S. Endres, R. Ghorbani, S. C. Clark, and C. A. Dinarello, “Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF,” Blood, vol. 75, no. 1, pp. 40–47, 1990. View at Google Scholar · View at Scopus
  58. A. Steensberg, C. P. Fischer, C. Keller, K. Møller, and B. K. Pedersen, “IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans,” American Journal of Physiology, vol. 285, no. 2, pp. E433–E437, 2003. View at Google Scholar · View at Scopus
  59. H. Tilg, C. A. Dinarello, and J. W. Mier, “IL-6 and APPs: anti-inflammatory and immunosuppressive mediators,” Immunology Today, vol. 18, no. 9, pp. 428–432, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Tilg, E. Trehu, M. B. Atkins, C. A. Dinarello, and J. W. Mier, “Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55,” Blood, vol. 83, no. 1, pp. 113–118, 1994. View at Google Scholar · View at Scopus
  61. T. van der Poll, M. Levi, C. E. Hack et al., “Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees,” Journal of Experimental Medicine, vol. 179, no. 4, pp. 1253–1259, 1994. View at Google Scholar · View at Scopus
  62. L. Z. Xiao, N. Topley, T. Ito, and A. Phillips, “Interleukin-6 regulation of transforming growth factor (TGF)-β receptor compartmentalization and turnover enhances TGF-β1 signaling,” The Journal of Biological Chemistry, vol. 280, no. 13, pp. 12239–12245, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Rincon, “Interleukin-6: from an inflammatory marker to a target for inflammatory diseases,” Trends in Immunology, vol. 33, no. 11, pp. 571–577, 2012. View at Google Scholar
  64. R. Bonecchi, G. Bianchi, P. P. Bordignon et al., “Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s,” Journal of Experimental Medicine, vol. 187, no. 1, pp. 129–134, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Estaquier, T. Idziorek, W. Zou et al., “T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons,” Journal of Experimental Medicine, vol. 182, no. 6, pp. 1759–1767, 1995. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Puccetti, M. L. Belladonna, and U. Grohmann, “Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity,” Critical Reviews in Immunology, vol. 22, no. 5-6, pp. 373–390, 2002. View at Google Scholar · View at Scopus
  67. G. Trinchieri, “Interleukin-12 and the regulation of innate resistance and adaptive immunity,” Nature Reviews Immunology, vol. 3, no. 2, pp. 133–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. U. Boehm, T. Klamp, M. Groot, and J. C. Howard, “Cellular responses to interferon-gamma,” Annual Review of Immunology, vol. 15, pp. 749–795, 1997. View at Google Scholar
  69. T. Calandra, J.-D. Baumgartner, G. E. Grau et al., “Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock,” Journal of Infectious Diseases, vol. 161, no. 5, pp. 982–987, 1990. View at Google Scholar · View at Scopus
  70. S. B. Flohé, H. Agrawal, S. Flohé, M. Rani, J. M. Bangen, and F. U. Schade, “Diversity of interferon γ and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis,” Molecular Medicine, vol. 14, no. 5-6, pp. 247–256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Leentjens, M. Kox, R. M. Koch et al., “Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study,” American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 9, pp. 838–845, 2012. View at Google Scholar
  72. H. Okamura, S. Kashiwamura, H. Tsutsui et al., “Regulation of interferon-gamma production by IL-12 and IL-18,” Current Opinion in Immunology, vol. 10, no. 3, pp. 259–264, 1998. View at Google Scholar
  73. E. F. Wheelock, “Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin,” Science, vol. 149, no. 3681, pp. 310–311, 1965. View at Google Scholar · View at Scopus
  74. J. Bernhagen, T. Calandra, R. A. Mitchell et al., “MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia,” Nature, vol. 365, no. 6448, pp. 756–759, 1993. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Bernhagen, R. Krohn, H. Lue et al., “MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment,” Nature Medicine, vol. 13, no. 5, pp. 587–596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Bucala and S. C. Donnelly, “Macrophage migration inhibitory factor: a probable link between inflammation and cancer,” Immunity, vol. 26, no. 3, pp. 281–285, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. T. Calandra, J. Bernhagen, C. N. Metz et al., “MIF as a glucocorticoid-induced modulator of cytokine production,” Nature, vol. 377, no. 6544, pp. 68–71, 1995. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Calandra, J. Bernhagen, R. A. Mitchell, and R. Bucala, “The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor,” Journal of Experimental Medicine, vol. 179, no. 6, pp. 1895–1902, 1994. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Calandra, B. Echtenacher, D. Le Roy et al., “Protection from septic shock by neutralization of macrophage migration inhibitory factor,” Nature Medicine, vol. 6, no. 2, pp. 164–170, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Calandra and T. Roger, “Macrophage migration inhibitory factor: a regulator of innate immunity,” Nature Reviews Immunology, vol. 3, no. 10, pp. 791–800, 2003. View at Google Scholar · View at Scopus
  81. L. Leng, W. Wang, T. Roger et al., “Glucocorticoid-induced MIF expression by human CEM T cells,” Cytokine, vol. 48, no. 3, pp. 177–185, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Merk, R. A. Mitchell, S. Endres, and R. Bucala, “D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family,” Cytokine, vol. 59, no. 1, pp. 10–17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. R. A. Mitchell, H. Liao, J. Chesney et al., “Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 345–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Roger, A. Chanson, M. Knaup-Reymond, and T. Calandra, “Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1,” European Journal of Immunology, vol. 35, no. 12, pp. 3405–3413, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. R. D. W. Malefyt, J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries, “Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes,” Journal of Experimental Medicine, vol. 174, no. 5, pp. 1209–1220, 1991. View at Google Scholar · View at Scopus
  86. D. F. Fiorentino, A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra, “IL-10 inhibits cytokine production by activated macrophages,” The Journal of Immunology, vol. 147, no. 11, pp. 3815–3822, 1991. View at Google Scholar · View at Scopus
  87. S. Q. Latifi, M. A. O'Riordan, and A. D. Levine, “Interleukin-10 controls the onset of irreversible septic shock,” Infection and Immunity, vol. 70, no. 8, pp. 4441–4446, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Seitz, P. Loetscher, B. Dewald, H. Towbin, H. Gallati, and M. Baggiolini, “Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts,” European Journal of Immunology, vol. 25, no. 4, pp. 1129–1132, 1995. View at Google Scholar · View at Scopus
  89. G. C. Blobe, W. P. Schiemann, and H. F. Lodish, “Role of transforming growth factor β in human disease,” The New England Journal of Medicine, vol. 342, no. 18, pp. 1350–1358, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Bogdan and C. Nathan, “Modulation of macrophage function by transforming growth factor β, interleukin-4, and interleukin-10,” Annals of the New York Academy of Sciences, vol. 685, pp. 713–739, 1993. View at Google Scholar · View at Scopus
  91. C. Marie, J. M. Cavaillon, and M. R. Losser, “Elevated levels of circulating transforming growth factor-beta 1 in patients with the sepsis syndrome,” Annals of internal medicine, vol. 125, no. 6, pp. 520–521, 1996. View at Google Scholar · View at Scopus
  92. A. Pellacani, P. Wiesel, S. Razavi et al., “Down-regulation of high mobility group-I(Y) protein contributes to the inhibition of nitric-oxide synthase 2 by transforming growth factor-β1,” The Journal of Biological Chemistry, vol. 276, no. 2, pp. 1653–1659, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. M. B. Sporn and A. B. Roberts, “Transforming growth factor-β: multiple actions and potential clinical applications,” Journal of the American Medical Association, vol. 262, no. 7, pp. 938–941, 1989. View at Google Scholar · View at Scopus
  94. M. Turner, D. Chantry, P. Katsikis, A. Berger, F. M. Brennan, and M. Feldmann, “Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-β,” European Journal of Immunology, vol. 21, no. 7, pp. 1635–1639, 1991. View at Google Scholar · View at Scopus
  95. S. M. Opal and V. A. DePalo, “Anti-inflammatory cytokines,” Chest, vol. 117, no. 4, pp. 1162–1172, 2000. View at Google Scholar · View at Scopus
  96. R. A. Seder, W. E. Paul, M. M. Davis, and B. F. de st. Groth, “The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice,” Journal of Experimental Medicine, vol. 176, no. 4, pp. 1091–1098, 1992. View at Google Scholar · View at Scopus
  97. J.-M. Cavaillon, C. Munoz, C. Fitting, B. Misset, and J. Carlet, “Circulating cytokines: the tip of the iceberg?” Circulatory Shock, vol. 38, no. 2, pp. 145–152, 1992. View at Google Scholar · View at Scopus
  98. T. S. Blackwell and J. W. Christman, “Sepsis and cytokines: current status,” British Journal of Anaesthesia, vol. 77, no. 1, pp. 110–117, 1996. View at Google Scholar · View at Scopus
  99. N. Aikawa, “Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults,” Nippon Geka Gakkai Zasshi, vol. 97, no. 9, pp. 771–777, 1996. View at Google Scholar · View at Scopus
  100. W. G. Junger, D. B. Hoyt, F. C. Liu, W. H. Loomis, and R. Coimbra, “Immunosuppression after endotoxin shock: the result of multiple anti-inflammatory factors,” Journal of Trauma, vol. 40, no. 5, pp. 702–709, 1996. View at Google Scholar · View at Scopus
  101. B. M. Tang, S. J. Huang, and A. S. McLean, “Genome-wide transcription profiling of human sepsis: a systematic review,” Critical Care, vol. 14, no. 6, article R237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. C. E. Hack, L. A. Aarden, and L. G. Thijs, “Role of cytokines in sepsis,” Advances in Immunology, vol. 66, pp. 101–195, 1997. View at Google Scholar · View at Scopus
  103. T. van der Poll and S. J. H. van Deventer, “Cytokines and anticytokines in the pathogenesis of sepsis,” Infectious Disease Clinics of North America, vol. 13, no. 2, pp. 413–426, 1999. View at Publisher · View at Google Scholar · View at Scopus
  104. C. Dinarello, W. Arend, J. Sims et al., “IL-1 family nomenclature,” Nature Immunology, vol. 11, no. 11, article 973, 2010. View at Google Scholar
  105. M. Kapoor, J. Martel-Pelletier, D. Lajeunesse, J. Pelletier, and H. Fahmi, “Role of proinflammatory cytokines in the pathophysiology of osteoarthritis,” Nature Reviews Rheumatology, vol. 7, no. 1, pp. 33–42, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Lewis, L. A. Tartaglia, A. Lee et al., “Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 7, pp. 2830–2834, 1991. View at Google Scholar · View at Scopus
  107. M. Bhatia and S. Moochhala, “Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome,” Journal of Pathology, vol. 202, no. 2, pp. 145–156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. P. Selby, S. Hobbs, C. Viner et al., “Tumour necrosis factor in man: clinical and biological observations,” British Journal of Cancer, vol. 56, no. 6, pp. 803–808, 1987. View at Google Scholar · View at Scopus
  109. M. L. Sherman, D. R. Spriggs, K. A. Arthur, K. Imamura, E. Frei III, and D. W. Kufe, “Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism,” Journal of Clinical Oncology, vol. 6, no. 2, pp. 344–350, 1988. View at Google Scholar · View at Scopus
  110. T. van der Poll, H. R. Buller, H. ten Cate et al., “Activation of coagulation after administration of tumor necrosis factor to normal subjects,” The New England Journal of Medicine, vol. 322, no. 23, pp. 1622–1627, 1990. View at Google Scholar · View at Scopus
  111. A. Tewari, W. C. Buhles Jr., and H. F. Starnes Jr., “Preliminary report: effects of interleukin-1 on platelet counts,” The Lancet, vol. 336, no. 8717, pp. 712–714, 1990. View at Google Scholar · View at Scopus
  112. C. A. Dinarello, “Interleukin-1 and interleukin-1 antagonism,” Blood, vol. 77, no. 8, pp. 1627–1652, 1991. View at Google Scholar · View at Scopus
  113. S. Okusawa, J. A. Gelfand, T. Ikejima, R. J. Connolly, and C. A. DInarello, “Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition,” The Journal of Clinical Investigation, vol. 81, no. 4, pp. 1162–1172, 1988. View at Google Scholar · View at Scopus
  114. J. G. Cannon, R. G. Tompkins, J. A. Gelfand et al., “Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever,” Journal of Infectious Diseases, vol. 161, no. 1, pp. 79–84, 1990. View at Google Scholar · View at Scopus
  115. D. G. Hesse, K. J. Tracey, Y. Fong et al., “Cytokine appearance in human endotoxemia and primate bacteremia,” Surgery Gynecology and Obstetrics, vol. 166, no. 2, pp. 147–153, 1988. View at Google Scholar · View at Scopus
  116. H. R. Michie, K. R. Manogue, D. R. Spriggs et al., “Detection of circulating tumor necrosis factor after endotoxin administration,” The New England Journal of Medicine, vol. 318, no. 23, pp. 1481–1486, 1988. View at Google Scholar · View at Scopus
  117. A. F. Suffredini, R. E. Fromm, M. M. Parker et al., “The cardiovascular response of normal humans to the administration of endotoxin,” The New England Journal of Medicine, vol. 321, no. 5, pp. 280–287, 1989. View at Google Scholar · View at Scopus
  118. C. Fahlman, F. W. Jacobsen, O. P. Veiby, I. K. McNiece, H. K. Blomhoff, and S. E. W. Jacobsen, “Tumor necrosis factor-α (TNF-α) potently enhances in vitro macrophage production from primitive murine hematopoietic progenitor cells in combination with stem cell factor and interleukin-7: novel stimulatory role of p55 TNF receptors,” Blood, vol. 84, no. 5, pp. 1528–1533, 1994. View at Google Scholar · View at Scopus
  119. D. Conte, M. Holcik, C. A. Lefebvre et al., “Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival,” Molecular and Cellular Biology, vol. 26, no. 2, pp. 699–708, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. H. Nakae, S. Endo, K. Inada, T. Takakuwa, and T. Kasai, “Changes in adhesion molecule levels in sepsis,” Research Communications in Molecular Pathology and Pharmacology, vol. 91, no. 3, pp. 329–338, 1996. View at Google Scholar
  121. M. Shimaoka and E. J. Park, “Advances in understanding sepsis,” European Journal of Anaesthesiology, vol. 25, no. 42, pp. 146–153, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. G. A. Spinas, U. Keller, and M. Brockhaus, “Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia,” The Journal of Clinical Investigation, vol. 90, no. 2, pp. 533–536, 1992. View at Google Scholar · View at Scopus
  123. D. B. Kuhns, W. G. Alvord, and J. I. Gallin, “Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans,” Journal of Infectious Diseases, vol. 171, no. 1, pp. 145–152, 1995. View at Google Scholar · View at Scopus
  124. W. Ertel, F. A. Scholl, H. Gallati et al., “Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis,” Archives of Surgery, vol. 129, no. 12, pp. 1330–1337, 1994. View at Google Scholar · View at Scopus
  125. B. Gardlund, J. Sjolin, A. Nilsson, M. Roll, C.-J. Wickerts, and B. Wretlind, “Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity,” Journal of Infectious Diseases, vol. 172, no. 1, pp. 296–301, 1995. View at Google Scholar · View at Scopus
  126. A. S. Goldie, K. C. H. Fearon, J. A. Ross et al., “Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome,” Journal of the American Medical Association, vol. 274, no. 2, pp. 172–177, 1995. View at Google Scholar · View at Scopus
  127. E. Fischer, M. A. Marano, K. J. Van Zee et al., “Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia,” The Journal of Clinical Investigation, vol. 89, no. 5, pp. 1551–1557, 1992. View at Google Scholar · View at Scopus
  128. A. A. Creasey, P. Stevens, J. Kenney et al., “Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli,” Circulatory Shock, vol. 33, no. 2, pp. 84–91, 1991. View at Google Scholar · View at Scopus
  129. P. Damas, D. Ledoux, M. Nys et al., “Cytokine serum level during severe sepsis in human IL-6 as a marker of severity,” Annals of Surgery, vol. 215, no. 4, pp. 356–362, 1992. View at Google Scholar · View at Scopus
  130. A. M. Cruickshank, W. D. Fraser, H. J. G. Burns, J. van Damme, and A. Shenkin, “Response of serum interleukin-6 in patients undergoing elective surgery of varying severity,” Clinical Science, vol. 79, no. 2, pp. 161–165, 1990. View at Google Scholar · View at Scopus
  131. R. C. Hoch, R. Rodriguez, T. Manning et al., “Effects of accidental trauma on cytokine and endotoxin production,” Critical Care Medicine, vol. 21, no. 6, pp. 839–845, 1993. View at Google Scholar · View at Scopus
  132. C. E. Hack, E. R. De Groot, R. J. F. Felt-Bersma et al., “Increased plasma levels of interleukin-6 in sepsis,” Blood, vol. 74, no. 5, pp. 1704–1710, 1989. View at Google Scholar · View at Scopus
  133. E. Borrelli, P. Roux-Lombard, G. E. Grau et al., “Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk,” Critical Care Medicine, vol. 24, no. 3, pp. 392–397, 1996. View at Publisher · View at Google Scholar · View at Scopus
  134. A. Waage, P. Brandtzaeg, A. Halstensen, P. Kierulf, and T. Espevik, “The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome,” Journal of Experimental Medicine, vol. 169, no. 1, pp. 333–338, 1989. View at Google Scholar · View at Scopus
  135. J. Preiser, D. Schmartz, P. van der Linden et al., “Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog,” Cytokine, vol. 3, no. 1, pp. 1–4, 1991. View at Google Scholar · View at Scopus
  136. I. Kushner and D. L. Rzewnicki, “The acute phase response: general aspects,” Bailliere's Clinical Rheumatology, vol. 8, no. 3, pp. 513–530, 1994. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Cuzzocrea, L. Sautebin, G. De Sarro et al., “Role of IL-6 in the pleurisy and lung injury caused by carrageenan,” The Journal of Immunology, vol. 163, no. 9, pp. 5094–5104, 1999. View at Google Scholar
  138. S. Cuzzocrea, G. De Sarro, G. Costantino et al., “Role of interleukin-6 in a non-septic shock model induced by zymosan,” European Cytokine Network, vol. 10, no. 2, pp. 191–203, 1999. View at Google Scholar · View at Scopus
  139. N. Pathan, C. A. Hemingway, A. A. Alizadeh et al., “Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock,” The Lancet, vol. 363, no. 9404, pp. 203–209, 2004. View at Publisher · View at Google Scholar · View at Scopus
  140. K. Yoshizawa, M. Naruto, and N. Ida, “Injection time of interleukin-6 determines fatal outcome in experimental endotoxin shock,” Journal of Interferon and Cytokine Research, vol. 16, no. 12, pp. 995–1000, 1996. View at Google Scholar · View at Scopus
  141. Z. Xing, J. Gauldie, G. Cox et al., “IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses,” The Journal of Clinical Investigation, vol. 101, no. 2, pp. 311–320, 1998. View at Google Scholar · View at Scopus
  142. D. G. Remick, G. Bolgos, S. Copeland, and J. Siddiqui, “Role of interleukin-6 in mortality from and physiologic response to sepsis,” Infection and Immunity, vol. 73, no. 5, pp. 2751–2757, 2005. View at Publisher · View at Google Scholar · View at Scopus
  143. L. L. Jones and D. A. A. Vignali, “Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily,” Immunologic Research, vol. 51, no. 1, pp. 5–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. M. L. Steinhauser, C. M. Hogaboam, N. W. Lukacs, R. M. Strieter, and S. L. Kunkel, “Multiple roles for IL-12 in a model of acute septic peritonitis,” The Journal of Immunology, vol. 162, no. 9, pp. 5437–5443, 1999. View at Google Scholar · View at Scopus
  145. D. A. Zisman, S. L. Kunkel, R. M. Strieter et al., “Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis,” Shock, vol. 8, no. 5, pp. 349–356, 1997. View at Google Scholar · View at Scopus
  146. P. M. Jansen, T. C. T. M. V. Kraan, I. W. de Jong et al., “Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-γ,” Blood, vol. 87, no. 12, pp. 5144–5151, 1996. View at Google Scholar · View at Scopus
  147. S. E. Moreno, J. C. Alves-Filho, T. M. Alfaya, J. S. da Silva, S. H. Ferreira, and F. Y. Liew, “IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture,” The Journal of Immunology, vol. 177, no. 5, pp. 3218–3224, 2006. View at Google Scholar · View at Scopus
  148. H. Weighardt, C. Heidecke, A. Westerholt et al., “Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis,” Annals of Surgery, vol. 235, no. 4, pp. 560–567, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. S. A. Stanilova, Z. T. Karakolev, G. S. Dimov et al., “High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors,” Intensive Care Medicine, vol. 31, no. 3, pp. 401–407, 2005. View at Google Scholar · View at Scopus
  150. H. Wu, C. Shih, C. Lin, C. Hua, and D. Chuang, “Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors,” Critical Care, vol. 15, no. 5, article R224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. Z. Wang, S. L. Reiner, S. Zheng, D. K. Dalton, and R. M. Locksley, “CD4+ effector cells default to the Th2 pathway in interferon γ-deficient mice infected with Leishmania major,” Journal of Experimental Medicine, vol. 179, no. 4, pp. 1367–1371, 1994. View at Google Scholar · View at Scopus
  152. S. Huang, W. Hendriks, A. Althage et al., “Immune response in mice that lack the interferon-γ receptor,” Science, vol. 259, no. 5102, pp. 1742–1745, 1993. View at Google Scholar · View at Scopus
  153. A. M. Cooper, D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme, “Disseminated tuberculosis in interferon γ gene-disrupted mice,” Journal of Experimental Medicine, vol. 178, no. 6, pp. 2243–2247, 1993. View at Publisher · View at Google Scholar · View at Scopus
  154. U. Müller, U. Steinhoff, L. F. L. Reis et al., “Functional role of type I and type II interferons in antiviral defense,” Science, vol. 264, no. 5167, pp. 1918–1921, 1994. View at Google Scholar · View at Scopus
  155. F. P. Heinzel, “The role of IFN-γ in the pathology of experimental endotoxemia,” The Journal of Immunology, vol. 145, no. 9, pp. 2920–2924, 1990. View at Google Scholar · View at Scopus
  156. B. D. Car, V. M. Eng, B. Schnyder et al., “Interferon γ receptor deficient mice are resistant to endotoxic shock,” Journal of Experimental Medicine, vol. 179, no. 5, pp. 1437–1444, 1994. View at Google Scholar · View at Scopus
  157. C. Munoz, J. Carlet, C. Fitting, B. Misset, J.-P. Bleriot, and J.-M. Cavaillon, “Dysregulation of in vitro cytokine production by monocytes during sepsis,” The Journal of Clinical Investigation, vol. 88, no. 5, pp. 1747–1754, 1991. View at Google Scholar · View at Scopus
  158. N. R. Ferguson, H. F. Galley, and N. R. Webster, “T helper cell subset ratios in patients with severe sepsis,” Intensive Care Medicine, vol. 25, no. 1, pp. 106–109, 1999. View at Publisher · View at Google Scholar · View at Scopus
  159. A. R. Rich and M. R. Lewis, “The nature of allergy in tuberculosis as revealed by tissue culture studies,” Bulletin of the Johns Hopkins Hospital, vol. 50, pp. 115–131, 1932. View at Google Scholar
  160. T. Calandra, L. A. Spiegel, C. N. Metz, and R. Bucala, “Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 19, pp. 11383–11388, 1998. View at Publisher · View at Google Scholar · View at Scopus
  161. M. Merk, J. Baugh, S. Zierow et al., “The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor,” The Journal of Immunology, vol. 182, no. 11, pp. 6896–6906, 2009. View at Publisher · View at Google Scholar · View at Scopus
  162. T. Roger, J. David, M. P. Glauser, and T. Calandra, “MIF regulates innate immune responses through modulation of Toll-like receptor 4,” Nature, vol. 414, no. 6866, pp. 920–924, 2001. View at Publisher · View at Google Scholar · View at Scopus
  163. X. Shi, L. Leng, T. Wang et al., “CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex,” Immunity, vol. 25, no. 4, pp. 595–606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. L. Leng, C. N. Metz, Y. Fang et al., “MIF signal transduction initiated by binding to CD74,” Journal of Experimental Medicine, vol. 197, no. 11, pp. 1467–1476, 2003. View at Publisher · View at Google Scholar · View at Scopus
  165. A. G. Rossi, C. Haslett, N. Hirani et al., “Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF): potential role in asthma,” The Journal of Clinical Investigation, vol. 101, no. 12, pp. 2869–2874, 1998. View at Google Scholar · View at Scopus
  166. A. Mikulowska, C. N. Metz, R. Bucala, and R. Holmdahl, “Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-lnduced arthritis in mice,” The Journal of Immunology, vol. 158, no. 11, pp. 5514–5517, 1997. View at Google Scholar · View at Scopus
  167. S. Lin, X. Yu, Y. Chen et al., “De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits,” Circulation Research, vol. 87, no. 12, pp. 1202–1208, 2000. View at Google Scholar · View at Scopus
  168. Y. P. de Jong, A. C. Abadia-Molina, A. R. Satoskar et al., “Development of chronic colitis is dependent on the cytokine MIF,” Nature Immunology, vol. 2, no. 11, pp. 1061–1066, 2001. View at Google Scholar
  169. Y. Al-Abed, D. Dabideen, B. Aljabari et al., “ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis,” The Journal of Biological Chemistry, vol. 280, no. 44, pp. 36541–36544, 2005. View at Publisher · View at Google Scholar · View at Scopus
  170. M. Bozza, A. R. Satoskar, G. Lin et al., “Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis,” Journal of Experimental Medicine, vol. 189, no. 2, pp. 341–346, 1999. View at Publisher · View at Google Scholar · View at Scopus
  171. N. Matsuda, J. Nishihira, Y. Takahashi, O. Kemmotsu, and Y. Hattori, “Role of macrophage migration inhibitory factor in acute lung injury in mice with acute pancreatitis complicated by endotoxemia,” American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 2, pp. 198–205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  172. S. Kobayashi, J. Nishihira, S. Watanabe, and S. Todo, “Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide,” Hepatology, vol. 29, no. 6, pp. 1752–1759, 1999. View at Publisher · View at Google Scholar · View at Scopus
  173. L. B. Garner, M. S. Willis, D. L. Carlson et al., “Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor,” American Journal of Physiology, vol. 285, no. 6, pp. H2500–H2509, 2003. View at Google Scholar · View at Scopus
  174. E. J. Miller, J. Li, L. Leng et al., “Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart,” Nature, vol. 451, no. 7178, pp. 578–582, 2008. View at Publisher · View at Google Scholar · View at Scopus
  175. M. Merk, S. Zierow, L. Leng et al., “The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF),” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 34, pp. E577–E585, 2011. View at Publisher · View at Google Scholar · View at Scopus
  176. A. Beishuizen, L. G. Thijs, C. Haanen, and I. Vermes, “Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 6, pp. 2811–2816, 2001. View at Publisher · View at Google Scholar · View at Scopus
  177. T. Brenner, S. Hofer, C. Rosenhagen et al., “Macrophage migration inhibitory factor (MIF) and manganese superoxide dismutase (MnSOD) as early predictors for survival in patients with severe sepsis or septic shock,” Journal of Surgical Research, vol. 164, no. 1, pp. e163–e171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  178. S. Yende, D. C. Angus, L. Kong et al., “The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia,” The FASEB Journal, vol. 23, no. 8, pp. 2403–2411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  179. P. Renner, T. Roger, P. Bochud et al., “A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease,” The FASEB Journal, vol. 26, no. 2, pp. 907–916, 2012. View at Publisher · View at Google Scholar · View at Scopus
  180. S. Doernberg, B. Schaaf, K. Dalhoff et al., “Association of macrophage migration inhibitory factor (MIF) polymorphisms with risk of meningitis from Streptococcus pneumoniae,” Cytokine, vol. 53, no. 3, pp. 292–294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  181. G. A. Awandare, J. J. Martinson, T. Were et al., “MIF (Macrophage Migration Inhibitory Factor) promoter polymorphisms and susceptibility to severe malarial anemia,” Journal of Infectious Diseases, vol. 200, no. 4, pp. 629–637, 2009. View at Publisher · View at Google Scholar · View at Scopus
  182. M. Howard, T. Muchamuel, S. Andrade, and S. Menon, “Interleukin 10 protects mice from lethal endotoxemia,” Journal of Experimental Medicine, vol. 177, no. 4, pp. 1205–1208, 1993. View at Google Scholar · View at Scopus
  183. M. Howard and A. O'Garra, “Biological properties of interleukin 10,” Journal of Clinical Immunology, vol. 12, no. 4, pp. 239–247, 1992. View at Google Scholar
  184. G. Y. Song, C. Chung, I. H. Chaudry, and A. Ayala, “What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant?” Surgery, vol. 126, no. 2, pp. 378–383, 1999. View at Publisher · View at Google Scholar · View at Scopus
  185. T. van der Poll, A. Marchant, W. A. Buurman et al., “Endogenous IL-10 protects mice from death during septic peritonitis,” The Journal of Immunology, vol. 155, no. 11, pp. 5397–5401, 1995. View at Google Scholar · View at Scopus
  186. L. Zeng, W. Gu, K. Chen et al., “Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies,” Critical Care, vol. 13, no. 6, article R188, 2009. View at Google Scholar · View at Scopus
  187. K. M. Gilbert, M. Thoman, K. Bauche, T. Pham, and W. O. Weigle, “Transforming growth factor-β1 induces antigen-specific unresponsiveness in naive T cells,” Immunological Investigations, vol. 26, no. 4, pp. 459–472, 1997. View at Google Scholar · View at Scopus
  188. Y. Y. Wan and R. A. Flavell, “TGF-β and regulatory T cell in immunity and autoimmunity,” Journal of Clinical Immunology, vol. 28, no. 6, pp. 647–659, 2008. View at Publisher · View at Google Scholar · View at Scopus
  189. F. Randow, U. Syrbe, C. Meisel et al., “Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor β,” Journal of Experimental Medicine, vol. 181, no. 5, pp. 1887–1892, 1995. View at Google Scholar · View at Scopus
  190. M. A. Perrella, C. M. Hsieh, W. S. Lee et al., “Arrest of endotoxin-induced hypotension by transforming growth factor beta1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 5, pp. 2054–2059, 1996. View at Google Scholar
  191. B. S. Pender, “Transforming growth factor β1 alters rat peritoneal macrophage mediator production and improves survival during endotoxic shock,” European Cytokine Network, vol. 7, no. 2, pp. 137–142, 1996. View at Google Scholar · View at Scopus
  192. S. Zanotti, A. Kumar, and A. Kumar, “Cytokine modulation in sepsis and septic shock,” Expert Opinion on Investigational Drugs, vol. 11, no. 8, pp. 1061–1075, 2002. View at Publisher · View at Google Scholar · View at Scopus
  193. S. Knapp, F. Thalhammer, G. J. Locker et al., “Prognostic value of MIP-1α, TGF-β2, sELAM-1, and sVCAM-1 in patients with gram-positive sepsis,” Clinical Immunology and Immunopathology, vol. 87, no. 2, pp. 139–144, 1998. View at Publisher · View at Google Scholar · View at Scopus
  194. A. Kumar, A. Kumar, B. Paladugu, J. Mensing, and J. E. Parrillo, “Transforming growth factor-β1 blocks in vitro cardiac myocyte depression induced by tumor necrosis factor-α, interleukin-1β, and human septic shock serum,” Critical Care Medicine, vol. 35, no. 2, pp. 358–364, 2007. View at Publisher · View at Google Scholar · View at Scopus
  195. J. Zamorano, H. Y. Wang, L. Wang, J. H. Pierce, and A. D. Keegan, “IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway,” The Journal of Immunology, vol. 157, no. 11, pp. 4926–4934, 1996. View at Google Scholar · View at Scopus
  196. M. Yanagida, H. Fukamachi, K. Ohgami et al., “Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells,” Blood, vol. 86, no. 10, pp. 3705–3714, 1995. View at Google Scholar · View at Scopus
  197. M. B. Lutz, M. Schnare, M. Menges et al., “Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF,” The Journal of Immunology, vol. 169, no. 7, pp. 3574–3580, 2002. View at Google Scholar · View at Scopus
  198. J. M. Baumhofer, B. G. Beinhauer, J. E. Wang et al., “Gene transfer with IL-4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence,” European Journal of Immunology, vol. 28, no. 2, pp. 610–615, 1998. View at Google Scholar
  199. O. Hultgren, M. Kopf, and A. Tarkowski, “Outcome of Staphylococcus aureus-triggered sepsis and arthritis in IL-4-deficient mice depends on the genetic background of the host,” European Journal of Immunology, vol. 29, no. 8, pp. 2400–2405, 1999. View at Google Scholar
  200. H. P. Wu, C. L. Wu, C. K. Chen et al., “The interleukin-4 expression in patients with severe sepsis,” Journal of Critical Care, vol. 23, no. 4, pp. 519–524, 2008. View at Google Scholar
  201. W. Gu, L. Zeng, L. Zhang et al., “Association of interleukin 4-589T/C Polymorphism with TH1 and TH2 bias and sepsis in chinese major trauma patients,” Journal of Trauma, vol. 71, no. 6, pp. 1583–1587, 2011. View at Publisher · View at Google Scholar · View at Scopus
  202. C. J. Fisher Jr., S. M. Opal, J. F. Dhainaut et al., “Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group,” Critical Care Medicine, vol. 21, no. 3, pp. 318–327, 1993. View at Google Scholar
  203. S. M. Opal, C. J. Fisher Jr., J. A. Dhainaut et al., “Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial,” Critical Care Medicine, vol. 25, no. 7, pp. 1115–1124, 1997. View at Publisher · View at Google Scholar · View at Scopus
  204. F. Zeni, B. Freeman, and C. Natanson, “Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment,” Critical Care Medicine, vol. 25, no. 7, pp. 1095–1100, 1997. View at Publisher · View at Google Scholar · View at Scopus
  205. J. Cohen and J. Carlet, “INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis,” Critical Care Medicine, vol. 24, no. 9, pp. 1431–1440, 1996. View at Google Scholar · View at Scopus
  206. W. R. Parrish, M. Gallowitsch-Puerta, C. J. Czura, and K. J. Tracey, “Experimental therapeutic strategies for severe sepsis: mediators and mechanisms,” Annals of the New York Academy of Sciences, vol. 1144, pp. 210–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  207. L. Ulloa and K. J. Tracey, “The “cytokine profile”: a code for sepsis,” Trends in Molecular Medicine, vol. 11, no. 2, pp. 56–63, 2005. View at Publisher · View at Google Scholar · View at Scopus
  208. J. B. Lubetsky, A. Dios, J. Han et al., “The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents,” The Journal of Biological Chemistry, vol. 277, no. 28, pp. 24976–24982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  209. L. Leng, L. Chen, J. Fan et al., “A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr mice,” The Journal of Immunology, vol. 186, no. 1, pp. 527–538, 2011. View at Publisher · View at Google Scholar · View at Scopus
  210. A. Arjona, H. G. Foellmer, T. Town et al., “Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion,” The Journal of Clinical Investigation, vol. 117, no. 10, pp. 3059–3066, 2007. View at Publisher · View at Google Scholar · View at Scopus
  211. R. J. Kerschbaumer, M. Rieger, D. Völkel et al., “Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF,” The Journal of Biological Chemistry, vol. 287, no. 10, pp. 7446–7455, 2012. View at Publisher · View at Google Scholar · View at Scopus
  212. A. A. Hare, L. Leng, S. Gandavadi et al., “Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF),” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 19, pp. 5811–5814, 2010. View at Publisher · View at Google Scholar · View at Scopus
  213. S. Kraemer, H. Lue, A. Zernecke et al., “MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism,” The FASEB Journal, vol. 25, no. 3, pp. 894–906, 2011. View at Publisher · View at Google Scholar · View at Scopus
  214. J. J. Presneill, T. Harris, A. G. Stewart, J. F. Cade, and J. W. Wilson, “A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 2, pp. 138–143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  215. A. J. Rosenbloom, P. K. Linden, A. Dorrance, N. Penkosky, M. H. Cohen-Melamed, and M. R. Pinsky, “Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients,” Chest, vol. 127, no. 6, pp. 2139–2150, 2005. View at Publisher · View at Google Scholar · View at Scopus
  216. H. C. Polk Jr., W. G. Cheadle, D. H. Livingston et al., “A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients,” American Journal of Surgery, vol. 163, no. 2, pp. 191–196, 1992. View at Publisher · View at Google Scholar · View at Scopus
  217. C. T. Esmon, “The interactions between inflammation and coagulation,” British Journal of Haematology, vol. 131, no. 4, pp. 417–430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  218. C. T. Esmon, “The protein C pathway,” Chest, vol. 124, supplement 3, pp. 26S–32S, 2003. View at Google Scholar · View at Scopus
  219. A. P. Neyrinck, K. D. Liu, J. P. Howard, and M. A. Matthay, “Protective mechanisms of activated protein C in severe inflammatory disorders,” British Journal of Pharmacology, vol. 158, no. 4, pp. 1034–1047, 2009. View at Publisher · View at Google Scholar · View at Scopus
  220. P. L. Vera, T. E. Wolfe, A. E. Braley, and K. L. Meyer-Siegler, “Thrombin induces macrophage migration inhibitory factor release and upregulation in urothelium: a possible contribution to bladder inflammation,” PLoS ONE, vol. 5, no. 12, Article ID e15904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  221. H. F. Galley, N. E. El Sakka, N. R. Webster, D. A. Lowes, and B. H. Cuthbertson, “Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions,” British Journal of Anaesthesia, vol. 100, no. 6, pp. 815–819, 2008. View at Publisher · View at Google Scholar · View at Scopus
  222. K. Okajima, “Regulation of inflammatory responses by natural anticoagulants,” Immunological Reviews, vol. 184, pp. 258–274, 2001. View at Publisher · View at Google Scholar · View at Scopus
  223. M. Schmidt-Supprian, C. Murphy, B. White et al., “Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes,” European Cytokine Network, vol. 11, no. 3, pp. 407–413, 2000. View at Google Scholar · View at Scopus
  224. P. Bilbault, T. Lavaux, A. Launoy et al., “Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients,” Critical Care Medicine, vol. 35, no. 1, pp. 69–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  225. F. P. da Silva and V. Nizet, “Cell death during sepsis: integration of disintegration in the inflammatory response to overwhelming infection,” Apoptosis, vol. 14, no. 4, pp. 509–521, 2009. View at Publisher · View at Google Scholar · View at Scopus
  226. F. B. Taylor Jr., A. Chang, and C. T. Esmon, “Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon,” The Journal of Clinical Investigation, vol. 79, no. 3, pp. 918–925, 1987. View at Google Scholar · View at Scopus
  227. G. R. Bernard, E. W. Ely, T. J. Wright et al., “Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis,” Critical Care Medicine, vol. 29, no. 11, pp. 2051–2059, 2001. View at Google Scholar · View at Scopus
  228. G. R. Bernard, J. Vincent, P. Laterre et al., “Efficacy and safety of recombinant human activated protein C for severe sepsis,” The New England Journal of Medicine, vol. 344, no. 10, pp. 699–709, 2001. View at Publisher · View at Google Scholar · View at Scopus
  229. R. P. Dellinger, M. M. Levy, J. M. Carlet et al., “Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008,” Critical Care Medicine, vol. 36, no. 1, pp. 296–327, 2008. View at Google Scholar
  230. V. M. Ranieri, B. T. Thompson, P. S. Barie et al., “Drotrecogin alfa (activated) in adults with septic shock,” The New England Journal of Medicine, vol. 366, no. 22, pp. 2055–2064, 2012. View at Google Scholar